The UK Dementia Research Institute issued a formal response to the Cochrane review on April 16, the day the review was published. The position is unambiguous: the review's conclusion that anti-amyloid antibody therapies provide no clinically meaningful benefit is "weakened" by the methodological choice to combine analyses of five drugs that failed in clinical trials with two drugs — lecanemab and donanemab — that succeeded and have been approved in several countries. [1] Alzheimer's Research UK, in a parallel statement, called the analysis a "study with major limitations." [2] The Alzheimer's Society's Dr. Richard Oakley said the review "makes the picture look bleaker than it really is." [3] The pushback is organized, signed, and published.
The Cochrane review itself examined data from 17 randomized controlled trials with a combined 20,342 participants. [4] Lead author Francesco Nonino, a neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna, concluded that anti-amyloid monoclonal antibody therapies "make little or no difference to people's symptoms and disease progression" while increasing the risk of brain swelling and microbleeds. [5] The seven therapies analyzed: aducanumab, bapineuzumab, crenezumab, donanemab, gantenerumab, lecanemab, and solanezumab — five of which were discontinued, two of which are currently approved. [4] [5] The headline conclusion was that 18 months of treatment produces effects below the established threshold for the minimum clinically important difference.
Tuesday's Cochrane vs. Health Canada framing read the meta-analysis against Health Canada's April 30 Kisunla approval as the divergent-verdict moment. Wednesday's frame is the second-order organized response: the academy-side rebuttal infrastructure that Wednesday Tuesday's piece named only in passing has now produced documents the regulators will read.
The UK Dementia Research Institute's argument is structural. "Of the 17 studies included, only two — for lecanemab and donanemab — relate to medicines now approved in the UK," the institute's response notes. [1] "The remainder focused on drugs that were not pursued after failing to show meaningful benefit, inevitably shaping the review's conclusions." Alzheimer's Research UK Executive Director Dr. Susan Kohlhaas: "Newer, longer-term evidence suggests that the approved treatments may deliver modest but sustained benefits beyond the 18-month horizons of earlier studies, yet this emerging data is not reflected in the review." [3] The argument is not that Cochrane is wrong about the failed drugs; it is that the meta-analytic average is being driven by drugs that no patient in the world is currently being prescribed.
The regulatory landscape around the dispute is unresolved. The UK's Medicines and Healthcare products Regulatory Agency licensed lecanemab and donanemab; the National Institute for Health and Care Excellence rejected NHS coverage in June 2025 on cost-effectiveness grounds, and that decision is being reconsidered after the manufacturers won an appeal. NICE is now on its third draft guidance — a guidance that lands into a published Cochrane review and an organized academy rebuttal at the same time. [3] Health Canada approved Kisunla (donanemab) on April 30, with the European Medicines Agency's prior endorsement and the U.S. FDA's existing approvals as comparators. [6] The Alzheimer's Society's position: the regulators have done the work the meta-analysis flattens.
The lay-FAQ infrastructure is also now in place. Recognition Health UK on April 20 published patient-facing material specifically addressing the Cochrane review's conclusions for British patients with mild cognitive impairment or early-stage Alzheimer's. The point of such material is to give a clinical patient and their family the language to interpret a published meta-analysis without misreading the headline. The infrastructure is the part the lost-science framing of these stories often misses: a regulator can be silent and the academy can still produce the document.
What makes this a divergence the paper carries — rather than a methodology paper that runs in pharma trade press — is the scale. Anti-amyloid antibody therapy was the single largest investment area in dementia research over the last decade. Lecanemab and donanemab are not stopgaps; they are the first generation of disease-modifying treatments approved by major regulators after thirty years of failure. The question of whether they actually slow disease at the population level, versus the question of whether they slow disease in narrowly selected trial cohorts, is genuinely open. The UK DRI is right that combining five failed compounds with two approved ones distorts the headline. Cochrane is right that the absolute clinical effect at 18 months is small. Both findings can hold.
The patient-facing question is what someone with newly diagnosed mild cognitive impairment, sitting in a Cambridge or Newcastle clinic this Wednesday morning, should do with the published evidence. The answer the academy-side organized response is offering is: the evidence is not "anti-amyloid does not work." The evidence is that two specific antibody therapies, in carefully selected early-stage patients, deliver a modest but real slowing — at significant cost, with non-trivial side-effect risk, and with real-world evidence still emerging. That answer requires a paragraph rather than a sentence, which is why the news cycle has handled it badly.
NICE's third draft is due. Lilly has not produced a same-week response to the Cochrane meta-analysis itself — the manufacturer's silence, while the institutional rebuttal does the public work, is itself the structural fact. The FDA has not commented in any post-marketing communication. The asymmetry between Cochrane (one paper, one team) and the rebuttal (UK DRI, ARUK, Alzheimer's Society, Recognition Health UK lay FAQ, NICE, MHRA, Health Canada, EMA, FDA) is, structurally, a victory for academy organization. It is also a story about how disease-modifying drug evaluation is now a multi-jurisdiction debate that runs in real time on Twitter and in the pages of Cochrane and the press releases of UK DRI.
The Cochrane authors' final recommendation — that future research focus on mechanisms beyond amyloid removal — is not contested by the rebuttal. Where the rebuttal stops short of the meta-analysis is the policy implication: that approved drugs should be reconsidered. UK DRI does not say that. ARUK does not say that. The rebuttal is asking the regulators to keep the drugs available while research continues into combination therapies, longer follow-up, and new targets. Cochrane is asking the field to redirect. The two requests are compatible. The headline is the only place they aren't.
-- NORA WHITFIELD, Chicago